ClinicalTrials.gg
CompletedNCT03794544Updated Feb 24, 2022Results posted

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

A Phase 2 interventional study of Durvalumab and Oleclumab in Resectable, Early-stage and NSCLC, sponsored by MedImmune LLC. Completed at 18 sites in 7 countries. Open to participants aged 18 Years to 102 Years. Per ClinicalTrials.gov, last updated 2022-02-24.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 102 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
44th of 94
84 · median 74
Started
2019
with 7 others
Phase 2
58 of 94
11 open now
Registered
36th of 94
by date
Lead sponsor
4 of 94
MedImmune LLC

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 44th largest by enrollment, is one of 8 that started in 2019, is one of 58 in phase 2, and was the 36th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 102 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Study D9108C00002 (NeoCOAST) is a platform study assessing the effectiveness and safety of neoadjuvant durvalumab alone or in combination with novel agents in participants with resectable, early-stage (Stage I [>2cm] to IIIA) non-small cell lung cancer (NSCLC).

03

Conditions studied

  • Resectable
  • Early-stage
  • NSCLC

Keywords

  • Neoadjuvant
  • Non-small Cell Lung Cancer
  • Cancer
  • Lung
  • Resectable
  • Early-stage
  • Stage I
  • Stage II
  • Stage IIIA
  • Durvalumab
04

Who can participate

Ages eligible
18 Years to 102 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. and/or histologically-documented NSCLC

    1. Stage I (> 2 cm) to IIIA (for participants with N2 disease, only those with 1 single nodal station ≤ 3 cm are eligible) NSCLC according to the 8th edition of American Joint Committee on Cancer staging classification
    2. Amenable to complete surgical resection
    3. Have not received any other therapy for this condition
  2. Predicted (FEV1) ≥ 50%
  3. Predicted diffusing capacity of the lungs for carbon monoxide (DLCO) ≥ 50%
  4. 0 or 1
  5. Adequate organ function

Exclusion criteria

Exclusion Criteria:

  1. Participants with small-cell lung cancer or mixed small-cell lung cancer
  2. Participants who require or may require pneumonectomy
  3. Prior treatment with programmed cell death ligand-1 (), PD-L1, or cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors
  4. Current or prior use of medication within 14 days before the first dose of study drug.
  5. Active or prior documented or inflammatory disorders. The following are exceptions to this criterion:

    1. Participants with vitiligo or alopecia
    2. Participants with hypothyroidism on hormone replacement
    3. Any chronic skin condition that does not require systemic therapy
    4. Participants without active disease in the last 5 years may be included but only after consultation with the study physician
    5. Participants with celiac disease controlled by diet alone
  6. Pregnant or breast-feeding female
  7. Major surgical procedure within prior 30 days
  8. History of active primary immunodeficiency
  9. Active infection including tuberculosis, , , or
  10. (QTc) ≥ 470 ms
  11. Uncontrolled intercurrent illness that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the participant to give written
  12. Receipt of within 30 days prior to study entry
  13. History of another primary except for:

    1. Curative-treated malignancy with no known active disease > 2 years before enrollment on the study
    2. Curative-treated non-melanoma skin cancer and/or carcinoma in-situ
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Durvalumab 1500 mg

    Participants will receive durvalumab 1500 mg intravenously (IV) every 4 weeks (Q4W; on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).

    Drug: Durvalumab

  • Experimental
    Durvalumab 1500 mg + Oleclumab 3000 mg

    Participants will receive durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and oleclumab 3000 mg IV every 2 weeks (Q2W; on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).

    Drug: Durvalumab · Combination Product: Oleclumab

  • Experimental
    Durvalumab 1500 mg + Monalizumab 750 mg

    Participants will receive durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and monalizumab 750 mg IV Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).

    Drug: Durvalumab · Combination Product: Monalizumab

  • Experimental
    Durvalumab 1500 mg + Danvatirsen 200 mg

    Participants will receive danvatirsen 200 mg IV on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period), followed by durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and danvatirsen 200 mg IV every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).

    Drug: Durvalumab · Combination Product: Danvatirsen

Interventions

  • Durvalumab 1500 mg IV will be administered Q4W (on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.

    Also known as: MEDI4736

  • Combination productOleclumab

    Oleclumab 3000 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.

    Also known as: MEDI9447

  • Combination productMonalizumab

    Monalizumab 750 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.

    Also known as: IPH2201

  • Combination productDanvatirsen

    Danvatirsen 200 mg IV will be administered on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period) and later every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.

    Also known as: AZD9150

06

What researchers measure

Primary outcomes

  1. Major Pathological Response Rate

    Major pathological response rate is defined as percentage of participants with \<=10% residual viable tumor cells in the resected specimen.

    Time frame: Day 1 through Day 42

Secondary outcomes

  1. Pathological Complete Response (pCR) Rate

    The pCR rate is defined as percentage of participants with no residual viable tumor cells in the resected specimen.

    Time frame: Day 1 through Day 42

  2. Feasibility to Surgery

    Feasibility to surgery is defined as the percentage of participants who underwent the planned surgery within Days 29 to 42 after Week 1 Day 1.

    Time frame: Day 29 to Day 42 after Week 1 Day 1

  3. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

    Time frame: From Day 1 through Day 105

  4. Number of Participants With Grade 3 or Grade 4 Clinical Laboratory Toxicities

    Participants with Grade 3 or Grade 4 clinical laboratory toxicities are reported. Laboratory tests included hematology, coagulation, chemistry, and urinalysis.

    Time frame: From Day 1 through Day 105

  5. Number of Participants With Abnormal Vital Signs Reported as TEAEs

    Participants with abnormal vital sign reported as TEAEs are reported.

    Time frame: From Day 1 through Day 105

07

Results

Posted Feb 24, 2022
Limitations and caveats
The pharmacokinetic and immunogenicity samples are still being analyzed. Results for these outcome measures will be posted by 30Jun2022.

Participant flow

The trial was interrupted due to COVID-19 pandemic from 13Apr2020 to 07May2020.

Participant flow — Overall Study
MilestoneDurvalumab 1500 mgDurvalumab 1500 mg + Oleclumab 3000 mgDurvalumab 1500 mg + Monalizumab 750 mgDurvalumab 1500 mg + Danvatirsen 200 mg
Started27212016
Treated26212016
Completed26181915
Not completed1311
Withdrew: Withdrawal by subject1100
Withdrew: Death0001
Withdrew: Lost to follow-up0110
Withdrew: Other0100

Outcome measures

PrimaryMajor Pathological Response Rate

Major pathological response rate is defined as percentage of participants with \<=10% residual viable tumor cells in the resected specimen.

Time frame:
Day 1 through Day 42
Reported as:
Number · Percentage of participants
Major Pathological Response Rate
Percentage of participantsDurvalumab 1500 mgDurvalumab 1500 mg + Oleclumab 3000 mgDurvalumab 1500 mg + Monalizumab 750 mgDurvalumab 1500 mg + Danvatirsen 200 mg
Major Pathological Response Rate11.1 (2.4 to 29.2)19.0 (5.4 to 41.9)30.0 (11.9 to 54.3)31.3 (11.0 to 58.7)
SecondaryPathological Complete Response (pCR) Rate

The pCR rate is defined as percentage of participants with no residual viable tumor cells in the resected specimen.

Time frame:
Day 1 through Day 42
Reported as:
Number · Percentage of participants
Pathological Complete Response (pCR) Rate
Percentage of participantsDurvalumab 1500 mgDurvalumab 1500 mg + Oleclumab 3000 mgDurvalumab 1500 mg + Monalizumab 750 mgDurvalumab 1500 mg + Danvatirsen 200 mg
Pathological Complete Response (pCR) Rate3.7 (0.1 to 19.0)9.5 (1.2 to 30.4)10.0 (1.2 to 31.7)12.5 (1.6 to 38.3)
SecondaryFeasibility to Surgery

Feasibility to surgery is defined as the percentage of participants who underwent the planned surgery within Days 29 to 42 after Week 1 Day 1.

Time frame:
Day 29 to Day 42 after Week 1 Day 1
Reported as:
Number · Percentage of participants
Feasibility to Surgery
Percentage of participantsDurvalumab 1500 mgDurvalumab 1500 mg + Oleclumab 3000 mgDurvalumab 1500 mg + Monalizumab 750 mgDurvalumab 1500 mg + Danvatirsen 200 mg
Feasibility to Surgery84.6 (0.1 to 19.0)81.0 (1.2 to 30.4)90.0 (1.2 to 31.7)93.8 (1.6 to 38.3)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

Time frame:
From Day 1 through Day 105
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsDurvalumab 1500 mgDurvalumab 1500 mg + Oleclumab 3000 mgDurvalumab 1500 mg + Monalizumab 750 mgDurvalumab 1500 mg + Danvatirsen 200 mg
Any TEAEs18191513
Any TESAEs3215
SecondaryNumber of Participants With Grade 3 or Grade 4 Clinical Laboratory Toxicities

Participants with Grade 3 or Grade 4 clinical laboratory toxicities are reported. Laboratory tests included hematology, coagulation, chemistry, and urinalysis.

Time frame:
From Day 1 through Day 105
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or Grade 4 Clinical Laboratory Toxicities
ParticipantsDurvalumab 1500 mgDurvalumab 1500 mg + Oleclumab 3000 mgDurvalumab 1500 mg + Monalizumab 750 mgDurvalumab 1500 mg + Danvatirsen 200 mg
Alanine aminotransferase increased0002
Gamma glutamyl transferase increased0001
Lipase increased1110
Hyponatremia2000
Lymphocyte count decreased0001
SecondaryNumber of Participants With Abnormal Vital Signs Reported as TEAEs

Participants with abnormal vital sign reported as TEAEs are reported.

Time frame:
From Day 1 through Day 105
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Vital Signs Reported as TEAEs
ParticipantsDurvalumab 1500 mgDurvalumab 1500 mg + Oleclumab 3000 mgDurvalumab 1500 mg + Monalizumab 750 mgDurvalumab 1500 mg + Danvatirsen 200 mg
Palpitations1000
Pyrexia1210

Adverse events

Collected over From Day 1 through Day 105. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab 1500 mg0/26 (0%)3/26 (11.5%)18/26 (69.2%)
Durvalumab 1500 mg + Oleclumab 3000 mg0/21 (0%)2/21 (9.5%)19/21 (90.5%)
Durvalumab 1500 mg + Monalizumab 750 mg0/20 (0%)1/20 (5%)14/20 (70%)
Durvalumab 1500 mg + Danvatirsen 200 mg1/16 (6.3%)5/16 (31.3%)13/16 (81.3%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventDurvalumab 1500 mgDurvalumab 1500 mg + Oleclumab 3000 mgDurvalumab 1500 mg + Monalizumab 750 mgDurvalumab 1500 mg + Danvatirsen 200 mg
Covid-19Infections and infestations0/260/210/201/16
PneumoniaInfections and infestations1/261/210/201/16
Wound infectionInfections and infestations0/260/210/201/16
Bronchial anastomosis complicationInjury, poisoning and procedural complications0/260/210/201/16
Procedural haemorrhageInjury, poisoning and procedural complications0/260/210/201/16
Renal infarctRenal and urinary disorders0/260/210/201/16
HaemothoraxRespiratory, thoracic and mediastinal disorders0/260/210/201/16
Pleural effusionRespiratory, thoracic and mediastinal disorders0/260/210/201/16
PneumothoraxRespiratory, thoracic and mediastinal disorders0/260/211/200/16
Diabetic ketoacidosisMetabolism and nutrition disorders0/261/210/200/16
Most frequent other events
Showing 10 of 113
Most frequent other events
EventDurvalumab 1500 mgDurvalumab 1500 mg + Oleclumab 3000 mgDurvalumab 1500 mg + Monalizumab 750 mgDurvalumab 1500 mg + Danvatirsen 200 mg
FatigueGeneral disorders6/264/212/203/16
Procedural painInjury, poisoning and procedural complications5/260/210/200/16
DyspnoeaRespiratory, thoracic and mediastinal disorders3/261/210/203/16
NauseaGastrointestinal disorders2/263/210/201/16
AstheniaGeneral disorders3/263/210/200/16
CoughRespiratory, thoracic and mediastinal disorders1/263/211/202/16
Gastrooesophageal reflux diseaseGastrointestinal disorders0/260/210/202/16
Alanine aminotransferase increasedInvestigations1/260/210/202/16
ParaesthesiaNervous system disorders0/260/211/202/16
PruritusSkin and subcutaneous tissue disorders0/262/212/202/16

Baseline characteristics

Intent-to-treat (ITT) population included participants who were randomized and were analyzed according to their randomized treatment group.

Age, Continuous
Age, Continuous(Years)Durvalumab 1500 mgDurvalumab 1500 mg + Oleclumab 3000 mgDurvalumab 1500 mg + Monalizumab 750 mgDurvalumab 1500 mg + Danvatirsen 200 mgTotal
Mean67.1 ± 9.065.5 ± 7.565.1 ± 6.372.9 ± 7.967.3 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab 1500 mgDurvalumab 1500 mg + Oleclumab 3000 mgDurvalumab 1500 mg + Monalizumab 750 mgDurvalumab 1500 mg + Danvatirsen 200 mgTotal
Female1396634
Male1412141050
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Durvalumab 1500 mgDurvalumab 1500 mg + Oleclumab 3000 mgDurvalumab 1500 mg + Monalizumab 750 mgDurvalumab 1500 mg + Danvatirsen 200 mgTotal
Hispanic or Latino10023
Not Hispanic or Latino2621201481
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Durvalumab 1500 mgDurvalumab 1500 mg + Oleclumab 3000 mgDurvalumab 1500 mg + Monalizumab 750 mgDurvalumab 1500 mg + Danvatirsen 200 mgTotal
American Indian or Alaska Native00000
Asian10012
Native Hawaiian or Other Pacific Islander00000
Black or African American31105
White2320191375
More than one race00000
Unknown or Not Reported00022
08

Study locations

18 sites
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Fort Myers, Florida 33901, United States
  • Research Site
    Leesburg, Florida 34748, United States
  • Research Site
    Baltimore, Maryland 21231, United States
  • Research Site
    Buffalo, New York 14263, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Marseille Cedex 9, 13009, France
  • Research Site
    Toulouse CEDEX 09, 31059, France
  • Research Site
    Orbassano, 10043, Italy
  • Research Site
    Porto, 4200-072, Portugal
  • Research Site
    A Coruña, 15001, Spain
  • Research Site
    Barcelona, 08916, Spain
  • Research Site
    Zurich, 8091, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Jan 2021, 22 months.

Results were first posted in Feb 2022, 1 year 1 month after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 22 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2018
First posted
Jan 7, 2019
StartActual
Mar 8, 2019
Primary completionActual
Jan 13, 2021
CompletionActual
Jan 13, 2021
Results first posted
Feb 24, 2022
Last update
Feb 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03794544
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Jan 7, 2019
Start date
Mar 8, 2019
Primary completion
Jan 13, 2021
Completion
Jan 13, 2021
Results posted
Feb 24, 2022
Last update
Feb 24, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion